Dr. Sena-Esteves is investigating gene therapy techniques to replace the faulty gene causing Tay-Sachs Disease, a devastating neurological disorder. He's part of the Tay-Sachs Gene Therapy Consortium aiming to translate current results into a human clinical trial within three years.
A study of over 2,100 individuals with multiple sclerosis found that women were 1.4 times more likely to carry the HLA gene variant associated with MS than men. The researchers also discovered that women with this gene variant were more likely to pass it on to other women in their families.
Australian scientists discovered that changes to the SOX3 gene can lead to testis formation and male genitalia in an otherwise female embryo. This breakthrough will improve diagnosis and treatment for patients with disorders of sex development, which occur when the testes or ovaries do not develop properly.
A new study published in Spine found that patients who received early physical therapy after an episode of low back pain were less likely to receive epidural steroid injections, lumbar surgery, and frequent physician visits. This suggests that prompt access to physical therapy can lead to improved outcomes and reduced healthcare costs.
Researchers identified a plant clock gene that works in human cells and vice versa, with similar function. The study suggests convergent evolution as the explanation for this phenomenon, highlighting the importance of maintaining accurate circadian rhythms in both plants and humans.
Researchers at Indiana University School of Medicine introduce a potent anti-tumor gene into mice with metastatic melanoma, resulting in complete remission and permanent immune reconfiguration. The gene therapy uses modified lentivirus to deliver a T cell receptor gene that recognizes specific melanoma proteins.
The study confirms the 'malaria hypothesis', which suggests that the sickle cell gene provides protection against malaria, allowing it to survive and thrive in areas of intense transmission. The global map shows a significant geographical overlap between the frequency of the sickle cell gene and malaria prevalence.
Researchers at NewYork-Presbyterian/Weill Cornell report that gene therapy to the brain reverses depression-like behavior in mice, with human data backing up the promise of such therapy. Autopsy studies reveal significantly reduced levels of p11 protein in patients with severe depression.
A clinical trial of gene therapy for muscular dystrophy has uncovered an unexpected aspect of the disease, revealing that some patients mount an immune response to the dystrophin protein even before receiving treatment. The study suggests that tailoring treatment approaches to suit individual patient needs could lead to better outcomes.
Researchers studying gene therapy for Duchenne muscular dystrophy discovered a natural immunity to dystrophin, complicating experimental therapies. The immune response triggered by T cells may target muscle cells, resembling autoimmunity.
A new, fully characterized viral vector is introduced as a reference material to standardize gene therapy protocols in research applications and human clinical trials. The availability of this reference standard allows vector parameters to be expressed in common units, enabling comparison and normalization across laboratories.
A study analyzing Canadian data shows a decline in breast cancer incidence among postmenopausal women as hormone therapy prescriptions fell. The decline, which coincided with a drop in hormone replacement therapy use, suggests that HRT may be linked to an increased risk of breast cancer.
Scientists at the University of Granada have developed a new therapy for skin and lung cancer using a suicide coliphage-gene, demonstrating effectiveness in vitro and in vivo. The treatment involves inducing cell death in tumour cells, potentially reducing the need for chemotherapy.
Researchers at Tufts University develop nanoparticles to deliver therapeutic genes to the retina, delaying onset of eye disease and preserving vision. The treatment, using a gene for GDNF, shows temporary but significant protection against photoreceptor cell death.
Researchers successfully replaced a human gene to preserve photoreceptor function in mice with severe retinal degeneration. The study demonstrates improved function and survival of photoreceptors, validating a potential gene therapy design for patients affected by Leber congenital amaurosis.
Scientists have developed a new approach to deliver therapeutic genes into brain cancer cells, using chlorotoxin from deathstalker scorpion venom and nanoparticles of iron oxide. This method has shown promise in inducing nearly twice the amount of gene expression in brain cancer cells compared to traditional approaches.
Italian scientists have successfully completed preclinical trials for a gene transfer treatment that can correct the lack of beta-globin in patients' blood cells, a major step towards treating beta-thalassemia. The treatment uses genetically corrected stem cells to restore haemoglobin production and overcome the disorder.
Gene therapy holds promise in treating prostate cancer, but challenges remain in achieving effective treatment. Researchers call for better testing systems and innovative approaches to advance the field. Prostate cancer is a leading cause of cancer death among men in the US.
Researchers developed an experimental cure for Type 1 diabetes using gene therapy, which successfully reversed the disease in about half of nonobese diabetic mice. The treatment protected new beta cells from autoimmune attack by adding a protective gene, allowing them to function normally.
Researchers at Penn University successfully used gene therapy to restore retinal cone function and day vision in canines with inherited day blindness. The treatment was effective for younger dogs and held promise for future clinical trials.
Alcohol-dependent women with supportive spouses may benefit from couples therapy, which maintained gains longer than individual therapy. Women with depression also did better in couples therapy, highlighting the importance of social support for change.
The study found that about two-thirds of couples showed significant clinical improvement after therapy, and the integrative therapy approach was more effective than traditional therapy. Couples who started therapy committed to improving their relationship and were willing to work on themselves
Researchers found that only patients with a specific genetic mutation are eligible for gene therapy, which has shown promising results in treating Leber congenital amaurosis. Genetic testing can detect changes in the genome, but accurate interpretation is crucial to ensure correct treatment.
Scientists have successfully used gene therapy to restore vision in mice with retinitis pigmentosa, a degenerative eye disease. The treatment involved the use of compacted DNA nanoparticles, which improved structural and functional vision in affected mice, without any adverse effects.
A new gene therapy approach has shown promising results in treating spinal muscular atrophy (SMA) in mice by improving muscle strength, coordination, and locomotion. The treatment involves injecting the gene-carrying therapeutic directly into the brain and spinal cord of newborn mice.
A second dose of gene therapy has proven safe and effective in animal studies, suggesting that patients who benefit from treatment in one eye may experience similar benefits in the other. The study found no signs of toxic side effects or interference from unwanted immune reactions.
New analyses confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women, particularly those who begin therapy within 10 years of menopause. The risk is more pronounced among women who start therapy 10 years or more after menopause.
A new tool called PEG-POD significantly increases gene delivery to retinal cells, outperforming existing carriers and DNA alone. This breakthrough may help develop therapies for conditions like retinitis pigmentosa and age-related macular degeneration.
University of Florida researchers are developing a gene therapy to treat Pompe disease, which causes severe muscle weakness and breathing difficulties. The treatment involves delivering a corrective gene directly to the diaphragm using an adeno-associated virus, with clinical trials expected to begin soon.
Researchers from Boston University School of Medicine have discovered a gene therapy that can prevent the progression of emphysema by delivering therapeutic genes to lung tissue. The treatment achieved sustained expression of human alpha-1 antitrypsin protein, improving lung compliance and alveolar size in mice with emphysema.
Researchers have achieved significant success with gene therapy in treating adrenoleukodystrophy (ALD), a potentially fatal brain disorder. The treatment has arrested the progression of the disease in two boys, showing no adverse effects to date.
Gene therapy has been successfully tested in France, halting the progression of adrenoleukodystrophy in two children. The innovative approach uses a modified HIV virus to deliver a therapeutic gene to bone marrow cells, which then migrate to the brain and display correcting potential.
Researchers have successfully used a gene therapy technique to slow the onset of X-linked adrenoleukodystrophy, a severe brain disease, in two patients. The treatment involved introducing a therapeutic gene into blood cells using a lentiviral vector, which showed promise in slowing disease progression and improving neurological function.
A phase III study found that short-term hormone therapy added to radiation treatment significantly increases survival in medium-risk prostate cancer patients by 51% compared to those receiving radiation alone. In contrast, low-risk patients showed no significant benefit from this combination.
Researchers found proton therapy to have excellent early tolerance with minimal urinary and rectal toxicity. The study showed a low rate of Grade 3 genitourinary and gastrointestinal side effects, with the most common being minor rectal bleeding.
Researchers successfully used gene therapy to repair injured human donor lungs, making them suitable for transplantation. The technique improves lung function and reduces inflammation, offering a promising approach to increase organ availability and improve patient outcomes.
A gene therapy treatment has successfully restored vision in five children and seven adults with Leber's congenital amaurosis, a group of inherited blinding diseases. The treatment uses genes to produce light-sensitive pigments in the back of the eye, allowing patients to navigate low-light environments and perform daily activities.
Gene therapy has been shown to improve vision in children with Leber congenital amaurosis, a severe form of inherited retinal degeneration. The treatment resulted in significant improvements in both subjective and objective measurements of vision.
A new cancer gene has been identified as the cause of adenoid cystic carcinoma, a slow-growing but deadly form of cancer. The discovery could lead to quicker diagnosis and more effective treatment through genetic testing.
Scientists used gene transfer to increase heart muscle cell contractions, improving cardiac function and quality of life for patients. The fast molecular motor gene transfer showed promise in reversing the course of heart failure.
Researchers are conducting a phase II gene therapy trial using CERE-110 to treat patients with mild Alzheimer's disease. The study aims to determine the safety and benefits of injecting the gene into the brain, which produces Nerve Growth Factor to help nerve cells survive.
A study published in Gastroenterology found that men with chronic hepatitis C undergoing antiviral therapy experience common sexual dysfunction, including impairment of desire, function, and satisfaction. The average onset of sexual dysfunction was within four weeks of starting therapy.
Effective reperfusion therapy in AMI patients can cut individual risk of dying by half and save millions of European lives. Modern catheter-based reperfusion strategies are more effective than fibrinolytic agents, reducing infarct-related mortality by up to 37%.
Researchers created a new gene therapy vector that uses the same machinery as viruses to deliver therapeutic genes into cells' nuclei. This breakthrough improves efficiency and specificity of human gene therapy, paving the way for clinical applications.
Researchers have discovered a way to regulate gene therapy for Parkinson's disease by introducing an 'off switch' using the antibiotic doxycycline. This breakthrough addresses safety concerns and paves the way for safer treatment options.
A $3.5-million NIH grant will help advance a gene therapy for Tay-Sachs disease from animal tests to human clinical trials. The Boston-based consortium has successfully paired two genes in a single vector, which they believe will increase therapeutic efficiency and lower production costs.
Researchers discovered that genetic material regulators beyond the SHOX gene itself play a crucial role in developing growth disorders. A study of 893 patients with short stature found that enhancer mutations, far from the affected gene, can cause the same clinical symptoms as direct gene mutations.
MU researchers discovered a 'longevity' gene that energizes mice during exercise, potentially applicable to humans. The gene removes toxic free radicals from mitochondria, improving life quality and treating diseases like muscular dystrophy and diabetes.
Researchers have documented remarkable vision improvements in three young adults with Leber Congenital Amaurosis after receiving gene therapy. The patients continue to experience increased sensitivity to light, and one patient was able to read an illuminated clock for the first time at 1 year after treatment.
Researchers report significant visual benefits in three young adults with Leber congenital amaurosis, a previously untreatable form of blindness. The gene therapy, which restored the RPE65 protein necessary for vision production, has shown safety and stability over one year.
Researchers at University of North Carolina have discovered a new approach to delivering a corrected CF gene to lung cells using parainfluenza virus, which could potentially cure cystic fibrosis lung disease. The method has shown promise in laboratory models and may pave the way for future clinical trials.
Researchers at UNC School of Medicine have found an efficient way to deliver a corrected gene to lung cells, restoring normal function in tissue models. This breakthrough could lead to improved treatment options for cystic fibrosis patients.
Researchers developed an ideal strategy for developing HCV-specific gene therapy by identifying the OAS promoter as a potential target. The study demonstrated that the HCV-core protein activates the OAS promoter specifically and effectively, paving the way for potential targeting of HCV using this approach.
A new study identifies a genomic fragment that reduces the effect of a type 2 diabetes risk gene in mice. The researchers found that this fragment, known as a 'jumping gene,' diminishes the activity of the risk gene Zfp69. In overweight individuals with diabetes, the human equivalent of this gene is highly active.
Researchers at Cedars-Sinai have developed a novel gene therapy that uses immune cells to target glioblastoma multiforme. A specific biomarker, HMGB1, has been identified as an effective tool to monitor tumor response to this treatment.
Researchers at the University of Minnesota Medical School have successfully provided long-term expression of Factor VIII in hemophilia A mice using a new gene therapy approach, marking a promising step toward human clinical trials.
Researchers develop gene therapy approach to target Factor VIII in hemophilia A mice, reducing disease symptoms. L-Asparaginase degradation mechanism also uncovered, with potential for optimizing treatment.
Researchers at VIB develop efficient and safe gene delivery approach based on non-viral genetic elements called transposons, overcoming limitations of viral vectors. This technology may simplify gene therapy, improve safety and reduce costs, treating cancer and genetic disorders.
Scientists at the University of California, Berkeley and Los Alamos National Laboratory have developed a comprehensive numerical study of gene therapy. The research sheds light on the key factors that determine the success of dendrimers as gene delivery vehicles, including the charges of the dendrimers and their target cell membranes.
Researchers successfully transferred a gene to produce a protein necessary for healthy muscle fiber growth, increasing muscle-fiber size and producing the needed protein for at least six months. The findings demonstrate the feasibility of gene therapy for treating limb-girdle muscular dystrophy and other muscle disorders.